Top Ten most popular articles on Pharmafile.com this week
pharmafile | November 27, 2020 | News story | Medical Communications |
The top ten news stories this week once again focus on COVID-19 treatments, with the Canadian Government securing 26,000 doses of Eli Lilly’s monoclonal antibody therapy bamlanivimab to treat citizens infected with COVID-19, while five different coronavirus vaccines from China are being tested in Phase 3 trials around the world.
1. Russia’s Sputnik COVID-19 vaccine has 91.4% efficacy after 28 days, new interim data show
The National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) have released a statement saying the Sputnik V vaccine for COVID-19 has a 91.4% efficacy after 28 days, and over 95% efficacy 42 days after the first dose.
2. First recombinant influenza vaccine approved in the European Union
The European Commission (EC) has just approved its first recombinant influenza vaccine for the European Union, awarding marketing authorisation to Sanofi Pasteur’s quadrivalent recombinant influenza vaccine Supemtek to prevent influenza infection in patients aged at least 18 years old.
3. Largest clinical trial treating mild to moderate COVID-19 patients to take place in Africa
The world’s largest clinical trial investigating the treatment of patients with mild to moderate COVID-19 is set to begin in Africa.
4. Interim analysis for AstraZeneca’s COVID-19 vaccine finds 70% average efficacy
Hot on the heels of Moderna and Pfizer/BioNTech who both have released very promising data for their mRNA COVID-19 vaccine candidates, AstraZeneca has now unveiled the first interim analysis data for its own vaccine against the virus, with all results showing statistically significance.
5. Purdue Pharma pleads guilty to its role in the opioid crisis
Purdue Pharma has pleaded guilty to criminal charges over its role in fueling the opioid crisis which was driven by its prescription painkiller OxyContin.
6. ABPI warns that no-deal Brexit could disrupt medicines and vaccine delivery
The Association of the British Pharmaceutical Industry (ABPI) has warned that the supplies of crucial medicines and vaccines could be threatened in the event of a no-deal Brexit.
7. First multiple sclerosis clinical trial for patients who can’t walk to begin recruitment
The first clinical trial to focus on multiple sclerosis (MS) patients who can’t walk will begin enrolling patients next year.
8. Five Chinese coronavirus vaccines in overseas clinical trials
Five different coronavirus vaccines from China are being tested in Phase 3 trials around the world.
9. Eli Lilly and Ypsome partner to advance automated insulin delivery system
Eli Lilly has entered into a global non-exclusive agreement with Ypsomed for the advancement of an automated insulin delivery system for people with diabetes.
10. Canada secures 26,000 doses of Lilly therapy to treat COVID-19 in $32.5m deal
The Canadian Government has partnered up with Eli Lilly to secure 26,000 doses of the company’s monoclonal antibody therapy bamlanivimab to treat citizens infected with COVID-19.
Conor Kavanagh
